Effect of anti-relapse antimalarial compound CDRI 80/53 and primaquine on hepatic mixed function oxidase system of rhesus monkey

V. C. Pandey, S. K. Puri, S. K. Sahni, P. Srivastava, G. P. Dutta

Research output: Contribution to journalArticle

5 Scopus citations

Abstract

A potential anti-relapse antimalarial compound CDRI 80/53 [N1-(3-acetyl-4-5-dihydro-2-furanyl)-N4-(6-methoxy-8-quinolinyl)1,4-pentanediamine] at 7.5 mg/kg body weight and primaquine at 6.0 mg/kg body weight did not cause any significant change in the status of hepatic microsomal mixed function oxidase system of rhesus monkeys, when given orally for 7 days. Further, the extension of the treatment at the same dossier up to 21 days resulted in impairment of the different indices of the MFO system. The compound CDRI 80/53 inhibited cytochrome P-450, aminopyrine-N-demethylase, aniline and benzo(a)pyrene hydroxylases, cytochrome b5 and haem levels by 17, 11, 58, 0, 36 and 35% whereas the inhibition caused by primaquine was 34, 40, 72, 54, 39 and 38% respectively, establishing that the cytochrome P-450 dependent mono-oxygenase system of monkey liver was comparatively less suppressed by compound CDRI 80/53. The cessation of the compound/drug treatment resulted in almost complete reversal of all the MFO activities to normal in a period of about 6 weeks.

Original languageEnglish (US)
Pages (from-to)701-707
Number of pages7
JournalPharmacological Research
Volume22
Issue number6
DOIs
StatePublished - Jan 1 1990
Externally publishedYes

Keywords

  • CDRI 80/53
  • MFO system
  • anti-relapse antimalarial
  • primaquine

ASJC Scopus subject areas

  • Pharmacology

Fingerprint Dive into the research topics of 'Effect of anti-relapse antimalarial compound CDRI 80/53 and primaquine on hepatic mixed function oxidase system of rhesus monkey'. Together they form a unique fingerprint.

  • Cite this